NCT02245360 - Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG

Phleum pratense grass pollen allergen extract

Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days

DRUG

placebo

placebo tablet given once daily over 60 days

Trial Locations (15)

105077

Research facility ID ORG-001086, Moscow

115446

Research facility ID ORG-001018, Moscow

115478

Research facility ID ORG-001005, Moscow

119333

Research facility ID ORG-001009, Moscow

119991

Research facility ID ORG-001016, Moscow

123182

Research facility ID ORG-001006, Moscow

Research facility ID ORG-001085, Moscow

142190

Research facility ID ORG-001014, Moscow

193231

Research facility ID ORG-001007, Saint Petersburg

195030

Research facility ID ORG-001019, Saint Petersburg

198216

Research facility ID ORG-001008, Saint Petersburg

214019

Research facility ID ORG-001017, Smolensk

410028

Research facility ID ORG-001021, Saratov

443099

Research facility ID ORG-001015, Samara

450000

Research facility ID ORG-001020, Ufa